UBE2O targets Mxi1 for ubiquitination and degradation to promote lung cancer progression and radioresistance

Yumei Huang,Xijie Yang,Yanwei Lu,Ye Zhao,Rui Meng,Sheng Zhang,Xiaorong Dong,Shuangbing Xu,Gang Wu

DOI: https://doi.org/10.1038/s41418-020-00616-8

IF: 12.067

2020-09-08

Cell Death and Differentiation

Abstract:Abstract UBE2O, an E2/E3 hybrid ubiquitin-protein ligase, has been implicated in the regulation of adipogenesis, erythroid differentiation, and tumor proliferation. However, its role in cancer radioresistance remains completely unknown. Here, we uncover that UBE2O interacts and targets Mxi1 for ubiquitination and degradation at the K46 residue. Furthermore, we show that genetical or pharmacological blockade of UBE2O impairs tumor progression and radioresistance in lung cancer in vitro and in vivo, and these effects can be restored by Mxi1 inhibition. Moreover, we demonstrate that UBE2O is overexpressed and negatively correlated with Mxi1 protein levels in lung cancer tissues. Collectively, our work reveals that UBE2O facilitates tumorigenesis and radioresistance by promoting Mxi1 ubiquitination and degradation, suggesting that UBE2O is an attractive radiosensitization target for the treatment of lung cancer.

cell biology,biochemistry & molecular biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role and mechanism of UBE2O in lung cancer progression and radiotherapy resistance. Specifically, the researchers aim to clarify whether UBE2O promotes the development of lung cancer and resistance to radiotherapy by targeting Mxi1 for ubiquitination and degradation. The answer to this question is of great significance for understanding how lung cancer cells acquire radiotherapy - resistant ability and for developing new lung cancer treatment methods.

The main findings of the paper include:
1. **Interaction between UBE2O and Mxi1**: The researchers verified through multiple experimental methods that UBE2O and Mxi1 have a physical interaction in vitro and in vivo.
2. **UBE2O promotes ubiquitination and degradation of Mxi1**: UBE2O can specifically promote ubiquitination of Mxi1 at the K46 site and subsequent proteasome degradation through its E2/E3 ubiquitin - ligase activity.
3. **Expression and function of UBE2O in lung cancer**: UBE2O is over - expressed in lung cancer tissues, and its expression level is negatively correlated with the protein level of Mxi1. Knocking down or inhibiting UBE2O can significantly inhibit the proliferation ability and radiotherapy resistance of lung cancer cells.
4. **Pharmacological blockade of UBE2O**: Using arsenic trioxide (ATO) as an inhibitor of UBE2O can effectively inhibit the growth of lung cancer cells and enhance their sensitivity to radiotherapy.

These findings not only reveal the important role of UBE2O in lung cancer development and radiotherapy resistance, but also suggest that UBE2O may be a potential target for lung cancer treatment.